Because of its decoy function, sVEGFR3 is used to therapeutically reduce VEGFR3 signaling in mice, for example, to suppress metastasis formation in a mammary cancer model (52), in lymphatic cancer models (53, 54), and for wet age-related macular degeneration and diabetic macular edema in a clinical trial (44). This evidence concerns the gene FLT4 and diabetic macular edema.